



This publication is part of AVAC's "Advocacy in Action: A comprehensive advocacy strategy for microbicide introduction," that is made possible by the support of the American people through the United States Agency for International Development (USAID) and the President's Emergency Plan for AIDS Relief (PEPFAR). The contents are the responsibility of AVAC and do not necessarily reflect the views of USAID or the United States Government.

Founded in 1995, AVAC is an international, non-profit organization that uses education, policy analysis, advocacy and community mobilization to accelerate the ethical development and global delivery of biomedical HIV prevention options as part of a comprehensive response to the pandemic. AVAC is based in the US, and focuses on issues and priorities in countries where prevention research and implementation are ongoing. Specifically, we seek to deliver proven HIV prevention tools for immediate impact; demonstrate and roll out new HIV prevention options; and develop long-term solutions needed to end the epidemic.



# Microbicides by the Numbers

Science, products,  
money and more



JULY 2016  
[avac.org](http://avac.org)


# Microbicides by the Numbers

Science, products, money and more


The term “microbicide” refers to substances being studied that could be used in the vagina and/or rectum to reduce the risk of HIV infection via sexual exposure. There are no licensed microbicides available today. Vaginal and rectal microbicides could help address some of HIV prevention’s greatest unmet needs. Millions of women and men today lack the power to insist that their sexual partners use condoms or other available prevention strategies. Simple, easy-to-use microbicides would help these individuals take control of their own health — while offering people everywhere an additional, needed option. The graphics below represent key facts about the microbicide field.

July, 2016

## Vaginal and Rectal Microbicide Products in the Clinical Trials Pipeline (Updated June 2016)




## DAPIVIRINE RING TIMELINE (Updated May 2016)



For a complete list of ongoing microbicide trials: AVAC HIV Prevention Research & Development Database (PxRD) [www.avac.org/pxrd](http://www.avac.org/pxrd)

## GLOBAL INVESTMENT IN MICROBICIDES R&D (2014)\*


**US\$ 193,000,000**



2014 data from HIV Vaccines & Microbicides Resource Tracking Working Group, Policy Cures G-FINDER and Battelle Global R&D Funding Forecast


\*2014 microbicide and HIV prevention R&D investment figures available at [www.resourcetracking.org](http://www.resourcetracking.org)

## DISTRIBUTION OF NEW ADULT HIV INFECTIONS BY AGE AND SEX, GLOBAL AND IN SUB-SAHARAN AFRICA (2015)



Adapted from UNAIDS Global Update 2016

## MICROBICIDE CLINICAL TRIAL PARTICIPANTS BY REGION (2014)



2014 data from HIV Vaccines & Microbicides Resource Tracking Working Group